[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-renal-disease-requiring-haemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-renal-disease-requiring-haemodialysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,81,106,134,160,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636829","impact-of-dialysis-duration-and-diuresis-on-bladder-capacity-and-compliance-in-end-stage-renal-disease-patients-awaiting-renal-transplant-100636829",false,"NCT07570771","IMPACT OF DIALYSIS DURATION AND DIURESIS ON BLADDER CAPACITY AND COMPLIANCE IN END STAGE RENAL DISEASE PATIENTS AWAITING RENAL TRANSPLANT","ESRD","Inclusion Criteria:\n\n* Patients aged 18-65 years diagnosed with end-stage renal disease (ESRD)\n* Patients on maintenance dialysis for a duration of 6 to 24 months\n* ESRD secondary to non-urological causes\n* Patients awaiting renal transplantation\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus\n* Patients with neurogenic bladder\n* Patients with prior urological surgeries\n* Patients with active urinary tract infection\n* Patients with pre-existing lower urinary tract symptoms before dialysis\n* Patients on medications affecting lower urinary tract function\n* Patients with neurological or systemic diseases affecting bladder function","ALL","18 Years","65 Years",{"count":20,"type":21},87,"ESTIMATED","01 Weeks","OBSERVATIONAL","Patients with end-stage renal disease (ESRD) who are on dialysis for a long time may experience bladder problems as their urine output decreases and normal bladder filling is lacking. As a result, bladder capacity may be reduced and compliance may deteriorate, which can impact the success of kidney transplantation.\n\nOur prospective observational study is designed to investigate how dialysis duration and residual urine output (diuresis) influence bladder capacity and compliance in ESRD patients who are waiting for kidney transplantation. The adult patients undergoing regular dialysis will be assessed clinically, and they will also be subjected to laboratory tests, imaging, and urodynamic studies.\n\nThrough this study, we aim to determine the frequency of bladder malfunction and its correlation with the length of dialysis and the amount of urine excretion. The results might enhance the pre-transplant workup and offer a basis for urological post-transplantation management that could minimize complications.",[26,27],"End-Stage Renal Disease Requiring Haemodialysis","Bladder Dysfunction",[29,30,31,32],"Dialysis Duration","Bladder Capacity","Bladder Compliance","Renal Transplant Candidates","RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":37},"2026-02-02",{"date":41,"type":21},"2027-02",{"name":43,"class":44},"Sindh Institute of Urology and Transplantation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100609172","evaluation-of-the-effectiveness-of-a-mobile-application-developed-for-hemodialysis-patients-100609172","NCT07211100","Evaluation of the Effectiveness of a Mobile Application Developed for Hemodialysis Patients.","Evaluation of the Impact of a Mobile Application Developed for Hemodialysis Patients on Treatment Adherence, Symptom Management and Clinical Parameters.","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed with end-stage renal disease (ESRD).\n* Receiving maintenance hemodialysis treatment for at least 3 months.\n* Able to use a smartphone and willing to install the mobile health application.\n* Voluntarily agreeing to participate in the study and providing written informed consent.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment, severe psychiatric disorders, or communication barriers that may interfere with participation.\n* Patients with visual or hearing impairments that prevent the use of the mobile application.\n* Patients who have undergone kidney transplantation or are scheduled for transplantation within the study period.\n* Patients with serious comorbid conditions requiring hospitalization (e.g., advanced cancer, severe heart failure).\n* Participation in another interventional clinical trial within the past 3 months.",{"count":54,"type":21},72,"INTERVENTIONAL",[57],"NA","This study aims to evaluate the effectiveness of a mobile health application developed for adult patients undergoing hemodialysis treatment. The mobile application includes modules on adherence to medication, diet, and fluid restrictions, symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, and motivational content. It also features reminder notifications, an \"Ask the Expert\" module, and personal symptom tracking.\n\nThe research will be conducted as a single-center, single-blind, randomized controlled experimental study. Participants will be assigned to intervention and control groups using block randomization. The intervention group will receive the mobile application, while the control group will receive standard care. Assessments will be carried out at baseline (T0), 1st month (T1), and 2nd month (T2).\n\nThe measurement tools to be used include the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ), Post-Dialysis Fatigue Scale, 5-D Itch Scale, Visual Analog Scale (VAS) for pain, and the Mobile Application Usability Scale. In addition, clinical parameters such as serum potassium, phosphorus, and albumin will be evaluated.\n\nA total of 72 patients (36 intervention, 36 control) will be included in the study. This study aims to assess the impact of a mobile health application on treatment adherence, symptom management, and clinical parameters among hemodialysis patients, and to develop a digital health model that can be integrated into nursing care.",[26,60],"Mobile Application",[62,63,64,65,66,67,68,69,70],"hemodialiysis","mobile application","mobil health","pain","fatigue","itching","nursingcare","adaptation","esrd","NOT_YET_RECRUITING","2025-09-29",{"date":74,"type":37},"2025-10-07",{"date":76,"type":21},"2025-11",{"date":78,"type":21},"2026-02",{"name":80,"class":44},"Saglik Bilimleri Universitesi",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":55,"phases":91,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100608431","phase-1-to-assess-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-kn060-in-esrd-dialysis-patients-100608431","NCT07201467","To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients","Phase 1b Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in Patients With End Stage Renal Disease Receiving Regular Hemodialysis","Inclusion Criteria:\n\n1. Male or female subjects aged between 18 and 80 years (inclusive);\n2. 1 8 kg \u002Fm \\^2 \\\u003CBMI \\\u003C2 8 kg \u002Fm\\^2 ;\n3. Diagnosis of ESRD and be receiving regular, stable hemodialysis treatment within the three months prior to screening: dialysis is performed through a functional, non-infected graft arteriovenous fistula \u002F autologous arteriovenous fistula ( AVG\u002FAVF ) ; dialysis is performed three times per week, with at least 3.5 hours per session ( at least 75% of dialysis sessions within the four weeks prior to randomization meet the this criteria) ;\n4. The clinical status of the underlying ESRD is stable (assessed by the investigator) ;\n5. Kt\u002FV ≥ 1.2 within 3 months before screening ;\n6. Male subjects: From the time they sign the informed consent form until 3 months after the last dose of KN060 , they agree to take effective contraceptive measures and avoid sperm donation ( effective contraceptive methods include: consistent scientific use of condoms , vasectomy , or partners who have undergone tubal ligation or hysterectomy, or have an intrauterine device implanted, etc. );\n7. Women who are infertile and have no plans to have children (surgical infertility: such as after hysterectomy, bilateral salpingectomy , bilateral oophorectomy; or natural menopause: amenorrhea for ≥ 12 months and serum follicle-stimulating hormone (FSH) at menopausal levels ).\n\nExclusion Criteria:\n\n1. A history of malignant tumor;\n2. History of mechanical\u002Fartificial heart valve replacement surgery;\n3. History of major medical events within 3 months before screening , such as acute coronary syndrome, stroke , major organ bleeding, acute heart failure, systemic thromboembolic events , major surgery, etc. , or history of AVF\u002FAVG functional loss;\n4. Using anticoagulant\u002Fantiplatelet drugs due to disease treatment , such as warfarin , dabigatran, rivaroxaban , clopidogrel , or aspirin \\>100 mg\u002Fday (investigators are allowed to use heparin \u002F low molecular weight heparin during dialysis, depending on the situation );\n5. There is a high risk of bleeding, or abnormal bleeding-related indicators:\n\n1） Bleeding requiring hospitalization or clinically significant active bleeding within 3 months before screening ; prolonged arteriovenous fistula compression time within the past month; 2） Platelet count (PLT) \\\u003C100 × 10\\^ 9 \u002FL ( PLT between 75-100 × 10\\^9 \u002FL , determined by the investigator after comprehensive evaluation), hemoglobin ( Hb ) \\\u003C 90 g\u002FL ; 3） Normalized ratio INR\\>1.4 , activated partial thromboplastin time ( APTT ) \\> 1.2 times ULN ; 4） Liver disease-related laboratory abnormalities: increased bleeding risk due to coagulation disorders , alanine aminotransferase (ALT) \\> 3 times ULN , aspartate aminotransferase ( AST) \\> 3 times ULN , total bilirubin (TB) \\> 2 times ULN and direct bilirubin proportion \\> 20%; 5） Poor blood pressure control in the past month before screening (judged by the investigator, such as repeated diastolic blood pressure ≥100 mmHg and\u002For systolic blood pressure ≥180 mmHg ) ; 6） Underwent brain, spinal or eye surgery (excluding cataract surgery) within three months before screening; 7） The patient has a bleeding disorder, a medical history that may increase the risk of bleeding, any condition that the investigator believes increases the risk of bleeding, or a history of severe bleeding disorders, such as massive gastrointestinal bleeding or cerebral hemorrhage ; 6. Supine blood pressure is \\\u003C 90\u002F50 mmHg , or \\> 170\u002F100 mmHg (one retest is allowed) during screening; 7. Electrocardiogram during screening: heart rate \\\u003C 45 beats \u002F min or \\> 110 beats \u002F min, QTcF \\> 500 ms, any significant arrhythmia or conduction abnormality ( e.g. Second degree or above atrioventricular block, preexcitation syndrome (except those who have undergone radical radiofrequency ablation) , non-sustained or sustained ventricular tachycardia (one retest is allowed); 8. History (\\\u003C1 year) of drug or alcohol abuse or dependence before screening; 9. Have a history of allergy, or be allergic to the experimental drug\u002Fsimilar drugs or excipients; 10. Human immunodeficiency virus (HIV ) infection, syphilis infection, active HBV infection (HBV -DNA\\>ULN ), active HCV infection (HCV - RNA \\> ULN ) ; 11. Participated in another clinical trial and received trial drugs within 3 months before screening (signing ICF); 12. Plan to receive a kidney transplant during the trial or within 3 months after completing this trial; 13. Xanthine, coffee (small amounts of caffeine from normal food sources, such as chocolate, are permitted), or alcohol cannot be prohibited during the study; 14. Any concomitant disease or condition that the investigator believes may interfere with the study drug, affect study data, or pose a risk to patient safety.","80 Years",{"count":90,"type":21},12,[92,93],"PHASE1","PHASE2","The primary objective of this study is to assess the safety and tolerability of KN060 in patients with end-stage renal disease on regular hemodialysis.\n\nThe secondary objectives to evaluate the pharmacokinetic and pharmacodynamic properties of multiple doses of KN060; to evaluate the immunogenicity of KN060; and to explore the efficacy of KN060 in preventing dialyzer and extracorporeal circuit thrombosis, arteriovenous fistula thrombosis in patients with end-stage renal disease undergoing regular hemodialysis. The main questions it aims to answer are:\n\n* Whether KN060 is safe for ESRD dialysis patients\n* Pharmacokinetic characteristics of KN060 in ESRD dialysis patients\n* Whether KN060 can effectively prevent dialyzer and extracorporeal circuit thrombosis Researchers will evaluate the safety, tolerability, Pharmacokinetics and Pharmacodynamics profile, dialyzer and extracorporeal circuit thrombosis, arteriovenous fistula thrombosis of KN060 in ESRD dialysis patients\n\nSubjects will :\n\n* Eligible subjects will receive KN060 2.5 mg\u002Fkg every two weeks for a total of 6 doses.\n* Assessed for the number, incidence, and severity of AEs, dialyzer thrombus, extracorporeal circuit thrombus, arteriovenous fistula thrombus, and time to hemostasis at the arteriovenous fistula puncture site.",[26],"2025-09-23",{"date":98,"type":37},"2025-10-01",{"date":100,"type":37},"2025-08-22",{"date":102,"type":21},"2027-12-15",{"name":104,"class":105},"Suzhou Alphamab Co., Ltd.","INDUSTRY",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":55,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100570522","impact-of-bevel-orientation-on-arteriovenous-fistula-puncture-in-hemodialysis-100570522","NCT06708338","Impact of Bevel Orientation on Arteriovenous Fistula Puncture in Hemodialysis","Impact of Bevel Orientation on Arteriovenous Fistula Puncture in Hemodialysis: A Multicenter Randomized Comparative Study","FAVORI","Inclusion Criteria:\n\n* male or female with Chronic Kidney Disease\n* patient requiring 4-hour hemodialysis sessions, 3 times per week, in a dialysis center\n* Native arteriovenous fistula (AVF) (without prosthesis), mature, with no prior puncture, located in the upper limb\n* First fistula for a hemodialysis patient\n* Expected duration of dialysis ≥ 1 year\n* Double-needle dialysis\n* Hemodialysis possible on AVF\n* Average AVF flow rate between 500 and 2,000 mL\u002Fmin\n* Affiliated with a social security scheme\n* Free and informed consent\n\nExclusion Criteria:\n\n* Auto-dialysis at home\n* Puncture using the buttonhole technique\n* Patient requiring AVF puncture with a catheter\n* Planned transplant within the next 12 months\n* Previous AVF creation, except for the fistula of interest\n* Patient with a history of cancer within the past 5 years or active cancer\n* Patient under court protection or guardianship\n* Pregnant and breast-feeding women\n* Patient with psychiatric pathologies or cognitive disorders\n* Patient follow-up difficult or impossible for geographical or other reasons, at the investigator's discretion","85 Years",{"count":116,"type":21},240,[57],"End-stage renal disease (ESRD) is a condition in which the filtration function of the kidneys has deteriorated, necessitating dialysis or transplantation. With an aging population, the number of patients undergoing dialysis for CKD is constantly increasing.\n\nThere are different types of dialysis treatment: hemodialysis and peritoneal dialysis.\n\nHemodialysis involves exchanges between blood and a dialysate (a liquid used to purify blood) via a dialyzer (artificial filter), coordinated by a generator. This method requires a vascular approach, of which there are 3 types: the arteriovenous fistula (AVF), the arteriovenous graft and the central venous catheter.\n\nThe AVF remains the vascular access of choice for hemodialysis sessions, and its preservation is an essential objective for patients with CKD.\n\nOne of the major challenges for AVFs is to achieve a successful puncture, an act performed around 310 times a year per patient, for dialysis performed three times a week with double needles. This repeated procedure can cause damage to the AVF, leading to complications such as stenosis, thrombosis, aneurysm, superficial infection, hematoma, bleeding, parietal rupture or dissection.\n\nHowever, there is no official recommendation on the most conservative puncture technique for AVF. In view of the number of patients concerned and the recurrence of puncture, it would seem essential to evaluate the impact of bevel orientation on the occurrence of complications during dialysis by means of a randomized prospective study.",[26],[121,122,123],"arteriovenous fistula","puncture technique","vascular approach","2025-07-30",{"date":126,"type":37},"2025-07-31",{"date":128,"type":21},"2025-12-01",{"date":130,"type":21},"2029-06-30",{"name":132,"class":44},"Centre Hospitalier Emile Roux",4,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":45},"100595501","inferior-vena-cava-collapsibility-index-and-intradialytic-hypotension-100595501","NCT07033273","Inferior Vena Cava Collapsibility Index and Intradialytic Hypotension","The Predictive Value of the Inferior Vena Cava Collapsibility Index for Intradialytic Hypotension: A Prospective Multicenter Observational Stud","IVC-HD","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with end-stage renal disease (ESRD).\n* Undergoing regular hemodialysis for at least three months.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Hemodynamically unstable patients or those requiring vasopressor support.\n* Patients with severe cardiac conditions, including congestive heart failure -classified as NYHA Class III-IV or severe valvular disease.\n* Patients with known allergies to dialysis filters.\n* Dialysis sessions terminated for reasons unrelated to hypotension (e.g., technical issues, patient request).\n* Patients who withdraw informed consent during the study.\n* Use of antihypertensive medications during dialysis sessions.\n* Inability to undergo ultrasound assessment due to factors such as severe obesity or wounds obstructing access.",{"count":143,"type":21},188,"This multicenter, prospective observational study aims to evaluate the predictive value of the Inferior Vena Cava Collapsibility Index (IVCCI), along with IVC maximum diameter (IVCmax) and IVC minimum diameter (IVCmin), for intradialytic hypotension in patients undergoing maintenance hemodialysis. The study will be conducted at The First Affiliated Hospital of Wannan Medical College, Wuhu City Second People's Hospital, Wuhu Hospital of Chinese Traditional Medicine, Wuhu Jinghu District Hospital, and Wuhu Guangji Hospital. Eligible participants are adults aged 18 years or older with diagnosed end-stage renal disease (ESRD), receiving regular hemodialysis for at least three months. Patients with acute kidney injury, severe cardiac conditions, or other factors likely to influence results will be excluded.\n\nUltrasound measurements of IVCCI, IVCmax, and IVCmin will be performed once, precisely at 1 hour after dialysis initiation. IVCmax will be measured during inspiration when the IVC is at its largest, and IVCmin during expiration when it is at its smallest. Blood pressure will be monitored continuously during the procedure. The primary objective is to assess the sensitivity, specificity, and optimal cutoff values of IVCCI, IVCmax, and IVCmin for predicting hypotension, aiming to provide a simple and non-invasive tool to facilitate personalized dialysis management and reduce intradialytic hypotension. A sample size of 188 participants is estimated, with data analyzed using ROC curves and multivariate regression methods. The study protocol adheres to ethical standards and regulatory requirements, demonstrating potential to improve patient safety and treatment outcomes.",[26,146],"Intradialytic Hypotension",[146,148,149,150,151],"Hemodialysis","Inferior Vena Cava Collapsibility Index","Blood Pressure Prediction","Vascular Ultrasonography","2025-06-14",{"date":154,"type":37},"2025-06-24",{"date":156,"type":37},"2025-01-27",{"date":126,"type":21},{"name":159,"class":44},"First Affiliated Hospital of Wannan Medical College",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":45},"100595500","predictive-value-of-carotid-ultrasonography-for-intradialytic-hypotension-100595500","NCT07033260","Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension","The Predictive Value of Carotid Corrected Flow Time and Peak Flow Velocity Variability for Intradialytic Hypotension: A Prospective Multicenter Observational Study","CUPID","Inclusion Criteria:\n\nAdults aged 18 to 80 years. Diagnosed with end-stage renal disease (ESRD). Undergoing maintenance hemodialysis for more than three months. Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\nPatients with significant carotid artery stenosis due to heavy atherosclerotic plaque (defined as more than 70% stenosis confirmed by ultrasound or angiography).\n\nHemodynamically unstable patients or those requiring vasopressor support. Patients with significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia).\n\nDialysis sessions terminated for reasons unrelated to hypotension (e.g., technical issues, patient request).\n\nUse of antihypertensive medications during dialysis sessions. Inability to undergo ultrasound assessment due to factors such as severe obesity or wounds obstructing access.\n\nPatients who withdraw informed consent during the study.",{"count":169,"type":21},183,"This multicenter, prospective observational study aims to evaluate the predictive value of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) for hypotension during maintenance hemodialysis. Conducted at The First Affiliated Hospital of Wannan Medical College, Wuhu City Second People's Hospital, Wuhu Hospital of Chinese Traditional Medicine, Wuhu Jinghu District Hospital, and Wuhu Guangji Hospital, the study will include adult patients (≥18 years) with end-stage renal disease (ESRD) on long-term hemodialysis for at least three months. Patients with acute kidney injury, severe cardiac conditions, or other factors affecting results will be excluded. Ultrasound assessments of FTc and PFVV will be performed once, at 1 hour after dialysis initiation. Blood pressure will be monitored during the procedure. The primary outcome is to determine the sensitivity, specificity, and optimal cutoff points of FTc and PFVV in predicting intradialytic hypotension. The estimated sample size is 183 participants, with analysis performed using ROC curves and multivariate regression. The protocol complies with ethical standards and aims to develop a simple, non-invasive, real-time tool to improve patient safety and individualized management during hemodialysis.",[146,26,172,148],"Uremia; Chronic",[174,175,176,177,148,178,179,180,181],"Carotid ultrasonography","Corrected flow time","Peak flow velocity variability","Intradialytic hypotension","Ultrasonographic predictors","Vascular ultrasonography","Fluid management","Dialysis safety",{"date":154,"type":37},{"date":184,"type":37},"2025-02-01",{"date":186,"type":21},"2025-08-30",{"name":159,"class":44},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":45},"100594699","pleth-variability-index-for-predicting-low-blood-pressure-during-maintenance-hemodialysis-100594699","NCT07022847","Pleth Variability Index for Predicting Low Blood Pressure During Maintenance Hemodialysis","The Value of Pleth Variability Index in Predicting Hypotension During Maintenance Hemodialysis: A Prospective Observational Multicenter Study","PVI-HD","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosis of end-stage renal disease and undergoing maintenance hemodialysis for more than 3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Severe cardiac arrhythmias or significant peripheral vascular disease that may interfere with PVI measurements.\n* Local edema, skin lesions, or other conditions that prevent accurate PVI monitoring.\n* History of hemodynamic instability unrelated to dialysis.\n* Pregnant or breastfeeding women.\n* Known allergy or contraindication to materials used in the hemodialysis circuit.\n* Unable to cooperate with study procedures.\n* Participation in another interventional clinical study within the past 30 days.",{"count":197,"type":21},200,"What is this study about? We are studying whether the Pleth Variability Index (PVI)-a simple, non-invasive measurement from a pulse oximeter-can help predict low blood pressure (hypotension) during routine maintenance hemodialysis. Low blood pressure during dialysis is a common and potentially serious complication. Our goal is to find out if monitoring PVI can help identify patients at risk, so that early action can be taken.\n\nWho can join? Adults aged 18 to 80 years. Patients who have been receiving maintenance hemodialysis regularly for more than 3 months.\n\nThose who are willing and able to participate and sign an informed consent form.\n\nWho cannot join? Patients with severe heart rhythm problems, severe peripheral circulation problems, or swelling that makes PVI measurement unreliable.\n\nPatients who are pregnant or breastfeeding. Patients allergic to the dialysis filter or unable to cooperate with the study procedures.\n\nWhat will happen during the study? PVI Measurement: Your PVI will be checked with a simple fingertip device before starting dialysis and again 30 minutes after dialysis begins.\n\nBlood Pressure Monitoring: Your blood pressure will be closely watched throughout the dialysis session.\n\nData Collection: Information about your age, medical history, medications, lab results, dialysis settings, and other standard measurements will be recorded.\n\nWhat are the benefits and risks? Benefits: By identifying patients at higher risk for low blood pressure during dialysis, the study may lead to safer and more comfortable dialysis treatment in the future.\n\nRisks: All measurements used in this study are safe and non-invasive, with no extra risk compared to routine care.\n\nYour Rights and Safety Participation is completely voluntary-you may leave the study at any time without affecting your medical care.\n\nThe study has been reviewed and approved by the hospital's ethics committee. Your privacy and personal data will be strictly protected.",[200,148,26,146],"Hypotension and Shock",[202,148,146,203,204,205,206,207],"Pleth Variability Index","Blood Pressure Monitoring","End-Stage Renal Disease","Non-invasive Monitoring","Predictive Marker","Maintenance Dialysis","2025-06-07",{"date":210,"type":37},"2025-06-15",{"date":184,"type":37},{"date":213,"type":21},"2025-06-30",{"name":159,"class":44}]